On August 5, 2020 Genor Biopharma Co. Inc reported that National Medical Products Administration (NMPA) has granted priority review status to its new drug application (NDA) for Geptanolimab, a PD-1 mAb, on July 28, 7 days after the NDA acceptance (Press release, Genor Biopharma, AUG 5, 2020, View Source [SID1234594762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Relapsed/refractory Peripheral T cell Lymphoma (PTCL) is the first indication that Genor targeted for its Geptanolimab. It is currently the first PD-1 mAb in China and globally being applied for this disease setting.